Literature DB >> 19879157

Wide-spectrum profile of inflammatory mediators in the plasma and scales of patients with psoriatic disease.

Irina Deeva1, Serena Mariani, Chiara De Luca, Valeria Pacifico, Luca Leoni, Desanka Raskovic, Zaira Kharaeva, Liudmila Korkina, Saveria Pastore.   

Abstract

Psoriasis is a chronic recurrent inflammatory disorder of the skin. Clinical subtypes include psoriasis vulgaris (PV), psoriatic arthropathy, and erythrodermic psoriasis. Aim of this study was to analyse relevant inflammatory mediators in the plasma of patients with distinct subtypes of active psoriasis, and in the scales of mild-to-moderate PV patients, and correlation to disease severity. Compared to healthy controls (n=10), patients affected by very severe forms of psoriasis (n=30) were characterized by increased plasma levels of IL-4, IL-6, MCP-1, VEGF and in particular PDGFbb. Each group with severe psoriasis had distinct characteristic features of plasma cytokine profile. Mild-to-moderate PV patients (n=35) showed higher levels of IL-4, IL-6, IL-10, and IL-13 when compared to healthy controls. No correlation was found between PV severity assessed by PASI (Psoriasis Area and Severity Index) and levels of these mediators. By contrast, disease severity correlated to scale levels of IP-10. For the first time, we found exaggerated circulating levels of the pro-angiogenic PDGFbb and VEGF in severe psoriasis. Evidence that the severity of skin symptoms correlated exclusively with scale levels of IP-10, but not with any up-regulated inflammatory mediator in plasma, suggests that distinct skin-independent processes contribute to the circulating cytokine profile in psoriasis. Copyright 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19879157     DOI: 10.1016/j.cyto.2009.09.014

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  14 in total

1.  Peripheral site acetylcholinesterase inhibitors targeting both inflammation and cholinergic dysfunction.

Authors:  Sherri Young; Karine Fabio; Christophe Guillon; Pramod Mohanta; Timothy A Halton; Diane E Heck; Robert A Flowers; Jeffrey D Laskin; Ned D Heindel
Journal:  Bioorg Med Chem Lett       Date:  2010-03-03       Impact factor: 2.823

2.  Aging enhances the basal production of IL-6 and CCL2 in vascular smooth muscle cells.

Authors:  Yang Song; Hua Shen; Dominik Schenten; Peiying Shan; Patty J Lee; Daniel R Goldstein
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-10-27       Impact factor: 8.311

3.  Two cases of Erythrodermic psoriasis treated with Golimumab.

Authors:  Mayssoun Kudsi; Mhd Amin Alzabibi; Mosa Shibani
Journal:  Ann Med Surg (Lond)       Date:  2022-06-08

4.  Serum levels and expression of IL-25 in patients with psoriatic erythroderma.

Authors:  Kinuko Irie; Toshiyuki Yamamoto
Journal:  Australas J Dermatol       Date:  2022-05-04       Impact factor: 2.481

5.  Flu-like symptoms and associated immunological response following therapy with botulinum toxins.

Authors:  José Fidel Baizabal-Carvallo; Joseph Jankovic; Jordan Feld
Journal:  Neurotox Res       Date:  2013-05-16       Impact factor: 3.911

Review 6.  Targeted Treatment for Erythrodermic Psoriasis: Rationale and Recent Advances.

Authors:  Shuai Shao; Gang Wang; Emanual Maverakis; Johann E Gudjonsson
Journal:  Drugs       Date:  2020-04       Impact factor: 9.546

7.  The pharmacodynamic impact of apremilast, an oral phosphodiesterase 4 inhibitor, on circulating levels of inflammatory biomarkers in patients with psoriatic arthritis: substudy results from a phase III, randomized, placebo-controlled trial (PALACE 1).

Authors:  Peter H Schafer; Peng Chen; Lorraine Fang; Andrew Wang; Rajesh Chopra
Journal:  J Immunol Res       Date:  2015-04-20       Impact factor: 4.818

8.  Integrated Haematological Profiles of Redox Status, Lipid, and Inflammatory Protein Biomarkers in Benign Obesity and Unhealthy Obesity with Metabolic Syndrome.

Authors:  Carla Lubrano; Giuseppe Valacchi; Palma Specchia; Lucio Gnessi; Elizaveta P Rubanenko; Elena A Shuginina; Arseny I Trukhanov; Liudmila G Korkina; Chiara De Luca
Journal:  Oxid Med Cell Longev       Date:  2015-05-18       Impact factor: 6.543

Review 9.  Psoriasis and Cardiovascular Risk-Do Promising New Biomarkers Have Clinical Impact?

Authors:  Sirje Kaur; Külli Kingo; Mihkel Zilmer
Journal:  Mediators Inflamm       Date:  2017-08-29       Impact factor: 4.711

10.  Erythrodermic psoriasis: pathophysiology and current treatment perspectives.

Authors:  Rasnik K Singh; Kristina M Lee; Derya Ucmak; Merrick Brodsky; Zaza Atanelov; Benjamin Farahnik; Michael Abrouk; Mio Nakamura; Tian Hao Zhu; Wilson Liao
Journal:  Psoriasis (Auckl)       Date:  2016-07-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.